Product Information
RANOLAZINE ER 500 MG TABLET is a generic product labeled by Ajanta Pharma USA Inc., priced at $0.1649 per EA under NDC 27241012502. Its NADAC has been published 372 times since Aug 21, 2019.
FDA first approved this application on May 28, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
500 mg/1
Manufacturer
Ajanta Pharma USA Inc.NDC
27241012502
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RANOLAZINEApproval Type
Generic (ANDA)
FDA Application
ANDA210054FDA Approved
5/28/2019
TE Code
AB
On Market Since
8/23/2019
Pharmacological Classes
Price Statistics
The NADAC for RANOLAZINE ER 500 MG TABLET has been published 372 times since Aug 21, 2019, and over the history we have for it it has declined 74.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1649 per EA |
|---|---|
| All-time high | $0.6542 (Sep 11, 2019) |
| All-time low | $0.1581 (Jul 22, 2026) |
| 52-week high | $0.1691 |
| 52-week low | $0.1581 |
| Median price | $0.2445 |
| Average price | $0.2952 |
| Largest weekly change | +17.6% (Aug 21, 2024) |
| Weeks tracked | 372 |
| Tracking since | Aug 21, 2019 |
Generic Alternatives
The matcher finds 13 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ajanta Pharma USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ranolazine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-anginal class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RANOLAZINE ER 500 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RANOLAZINE ER 500 MG TABLET, manufactured by Ajanta Pharma USA Inc., is $0.1649 per EA (NDC 27241012502), effective Sep 30, 2026.
How has the price of RANOLAZINE ER 500 MG TABLET changed over time?
Over the history we have for it, the NADAC for RANOLAZINE ER 500 MG TABLET has declined 74.8%. It has been tracked across 372 weekly CMS publications since Aug 21, 2019.
What are the highest and lowest recorded NADAC prices for RANOLAZINE ER 500 MG TABLET?
Since Aug 21, 2019, the NADAC for RANOLAZINE ER 500 MG TABLET has ranged from a low of $0.1581 (Jul 22, 2026) to a high of $0.6542 (Sep 11, 2019), with a median of $0.2445 per EA.
Are there cheaper alternatives to RANOLAZINE ER 500 MG TABLET?
Yes. 13 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RANOLAZINE ER 500 MG TABLET, is $0.1609 per EA — about 2% below RANOLAZINE ER 500 MG TABLET.
Who manufactures RANOLAZINE ER 500 MG TABLET?
RANOLAZINE ER 500 MG TABLET (NDC 27241012502) is labeled by Ajanta Pharma USA Inc., and CMS classifies it as a generic product.